IL22 and metabolic dysfunction-associated steatotic liver disease: Using rat NAFLD model, Zhu J et al. 30 found that IL-22 participated in BP therapy by activating JAK1/STAT3 signaling pathway and inhibiting apoptotic factor BAX.